

MODULE 1: ADMINISTRATIVE AND PRODUCT INFORMATION

1.3 Product information

1.3.1 Summary of Product Characteristics

1. NAME OF THE FINISHED PHARMACEUTICAL PRODUCT

Gentamicin Eye Drops BP 0.3 % w/v

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Standard batch size: 50.0 L/ 4950 Bottles						
Sr. No.	Ingredient	Reference	Quantity/ ml	Overage %	Quantity/ Batch	Function
1.	Gentamicin Sulfate	BP	3.0 mg	--	150* gm	Active Ingredient
2.	Benzalkonium Chloride Solution	BP	0.4 mg	--	20 gm	Preservative
3.	Disodium Edetate	BP	0.01 mg	--	0.500 gm	Chelating agent.
4.	Disodium Hydrogen Phosphate	BP	5.0 mg	--	250 gm	Buffering agent
5.	Sodium Dihydrogen Phosphate	BP	1.0 mg	--	50 gm	Buffering agent
6.	Sodium Chloride	BP	9.0 mg	--	450 gm	Tonicity agent
7.	Sulphuric Acid	BP	q.s. to pH	--	16.7 ml	Acidifying agent
8.	Water for Injection	BP	q.s. to 1.0 ml	--	q.s. to 50.0 Ltr.	Vehicle

Note: * Considering 100 % assay.

3. PHARMACEUTICAL FORM

Ophthalmic Solution

Kamla Lifesciences Ltd.

MODULE 1: ADMINISTRATIVE AND PRODUCT INFORMATION**4. Clinical particulars****4.1 Therapeutic indication**

Treatment of infections of the external structures of the eye and its adnexa caused by susceptible bacteria. Such infections include conjunctivitis, keratitis, kerato-conjunctivitis, corneal ulcers, blepharitis and blepharo-conjunctivitis, acute meibomianitis, episcleritis and dacryocystitis. It may be used for the prevention of ocular infection after: removal of a foreign body, burns or lacerations of the conjunctiva; damage from chemical or physical agents and after ocular surgery.

Also indicated for the treatment of otitis externa.

4.2 Posology and method of administration**Posology****Adults, including the elderly and children**

Eyes: Instill 1-2 drops into the affected eye up to six times a day, or more frequently if required. (severe infections may require 1 or 2 drops every fifteen to twenty minutes initially, reducing the frequency of instillation gradually as the infection is controlled).

4.3 Contraindications

Hypersensitivity to active substance, Gentamicin or to any of the excipients.

Should not be administered to patients with a known allergy to gentamicin and other aminoglycosides. Evidence exists that gentamicin may cause neuromuscular blockade and is therefore contra-indicated in myasthenia gravis and related conditions.

Perforated tympanic membrane.

4.4 Special warnings and precautions

Avoid prolonged use. Prolonged use may lead to skin sensitisation and the emergence of resistant organisms. Cross-sensitivity with other aminoglycoside antibiotics may occur.

Kamla Lifesciences Ltd.

MODULE 1: ADMINISTRATIVE AND PRODUCT INFORMATION

In severe infections, topical use of gentamicin should be supplemented with appropriate systemic antibiotic treatment.

Gentamicin may cause ototoxicity (vestibular damage; irreversible partial or total deafness) when given systemically or when applied topically to open wounds or damaged skin. This effect is dose-related and is enhanced by renal and/or hepatic impairment and is more likely in the elderly.

There have been observed cases of an increased risk of ototoxicity with aminoglycosides administered to patients with mitochondrial mutations, particularly the m.1555A>G mutation, including cases where the patient's aminoglycoside serum levels were within the recommended range. Some cases were associated with a maternal history of deafness and/or mitochondrial mutation. Mitochondrial mutations are rare, and the penetrance of this observed effect is unknown.

This formulation of Gentamicin Eye/Ear Drops contains benzalkonium chloride as a preservative which may be deposited in soft contact lenses. Hence, Gentamicin should not be used while wearing these lenses. The lenses should be removed before instillation of the drops and not reinserted earlier than 15 minutes after use.

Benzalkonium chloride has been reported to cause eye irritation, symptoms of dry eyes and may affect the tear film and corneal surface. Should be used with caution in dry eye patients and in patients where the cornea may be compromised. Patients should be monitored in case of prolonged use.

4.5 Interaction with other medicinal products and other forms of interaction

Potent diuretics such as ethacrynic acid and frusemide are believed to enhance any risk of ototoxicity whilst amphotericin B, cisplatin and cyclosporin and cephalosporins are potential enhancers of nephrotoxicity.

Concurrent use with other potentially nephrotoxic or ototoxic drugs should be avoided unless considered essential by the physician.

Kamla Lifesciences Ltd.

**MODULE 1: ADMINISTRATIVE AND PRODUCT
INFORMATION**

Neuromuscular blockade and respiratory paralysis have been reported in patients from the administration of aminoglycosides to patients who have received curare-type muscle relaxants during anaesthesia.

4.6 Fertility, pregnancy and lactation

Safety for use in pregnancy and lactation has not been established. Gentamicin should only be used in pregnancy or lactation when considered essential by the physician, after careful assessment of the potential risks and benefits.

4.7 Effects on ability to drive and use machines

Patients should be advised that the use of gentamicin in the eye may cause transient blurring of vision. If affected, patients should not drive or operate machinery until vision has cleared.

4.8 Undesirable effects

There are no modern clinical studies available that can be used to determine the frequency of undesirable effects. Therefore, all the undesirable effects listed are classed as “frequency unknown”.

Eye Disorders:-

Local sensitivity; blurred vision, eye irritation, burning sensation, stinging sensation, itching (eye pruritus)

Renal & Urinary Disorders:-

Gentamicin may cause nephrotoxicity when given systemically. However, it is likely that systemic absorption following topical administration does not constitute a comparable risk.

In the event of irritation, sensitivity or super-infection, treatment should be discontinued and appropriate therapy instituted.

Kamla Lifesciences Ltd.

MODULE 1: ADMINISTRATIVE AND PRODUCT INFORMATION**4.9 Overdose**

Haemodialysis and peritoneal dialysis will aid the removal from blood but the former is probably more efficient. Calcium salts given intravenously have been used to counter the neuromuscular blockade caused by gentamicin.

5. Pharmacological properties**5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Aminoglycoside antibacterial
ATC code: S03AA06

Gentamicin is a mixture of antibiotic substances produced by the growth of micromonospora purpurea. It is bactericidal with greater antibacterial activity than streptomycin, neomycin or kanamycin.

Gentamicin exerts a number of effects on cells of susceptible bacteria. It affects the integrity of the plasma membrane and the metabolism of RNA, but its most important effect is inhibition of protein synthesis at the level of the 30s ribosomal subunit.

5.2 Pharmacokinetic properties

Topical application of Gentamicin can result in some systemic absorption. Treatment of large areas can result in plasma concentrations of up to 1µg/ml.

Gentamicin is not readily absorbed from the gastro-intestinal tract < 10% is bound to plasma protein. following administration and is excreted >90% in the urine by glomerular filtration. The half-life for its elimination in normal patients is 2 to 3 hours, but can be increased in cases of renal insufficiency.

Effective plasma concentration is 4 - 8ug/ml

The volume of distribution (V_d) is 0.31/kg

5.3 Preclinical safety data

Nothing of relevance which is not included in other sections of the SPC.

Kamla Lifesciences Ltd.

**MODULE 1: ADMINISTRATIVE AND PRODUCT
INFORMATION**

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Benzalkonium Chloride Solution BP

Disodium Edetate BP

Disodium Hydrogen Phosphate BP

Sodium Dihydrogen Phosphate BP

Sodium Chloride BP

Sulphuric Acid BP

Water for Injection BP

6.2 Incompatibilities

Not Applicable

6.3 Shelf life

24 months.

6.4 Special precautions for storage

Store at a temperature not exceeding 30°C. Protect from light.

6.5 Nature and contents of container

A clear colourless liquid is filled in Sterile 10 ml LDPE Bottles with Nozzles and Seal caps.

6.6 Special precautions for disposal and other handling

Not Available

**MODULE 1: ADMINISTRATIVE AND PRODUCT
INFORMATION**

7. MARKETING AUTHORIZATION HOLDER

PRIYA PHARMACEUTICAL NIG LTD

No C-1, Airport Road, 2f, Kano, Kano State Nigeria

Manufacturer

M/S. KAMLA LIFESCIENCES LTD.

Plot No. G-84/1, Tarapur M.I.D.C, Boisar-401 506,

Tal. & Dist. Palghar, Maharashtra, India.

8. MARKETING AUTHORIZATION NUMBER

Not Available

9. DATE OF FIRST AUTHORIZATION/RENEWAL OF THE AUTHORIZATION

Not Available

10. DATE OF REVISION OF THE TEXT

New Application

Kamla Lifesciences Ltd.